QGEN Stock Overview
Offers sample to insight solutions that transform biological materials into molecular insights.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Innovative Diagnostics And Tactical Focus Poised To Propel Growth And Margin Enhancement
Qiagen N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$43.57 |
52 Week High | US$47.44 |
52 Week Low | US$35.81 |
Beta | 0.39 |
11 Month Change | -1.34% |
3 Month Change | 6.01% |
1 Year Change | 4.33% |
33 Year Change | -17.25% |
5 Year Change | 56.07% |
Change since IPO | 2,052.60% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued
Sep 24With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For
May 21Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
May 03Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
Feb 13Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings
Jan 23These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued
Oct 24Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
Sep 09Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jul 17Qiagen: Major Asset Growth Needed In Post-Covid World
Jun 22Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Apr 18Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued
Feb 14Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated
Feb 07If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity
Jan 18Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases
Jan 06A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jan 04Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati
Dec 13Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M
Nov 07We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Qiagen stock down after BHF downgrades rating to Neutral
Oct 10Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Oct 04Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate
Sep 14Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
Aug 25Is Qiagen (NYSE:QGEN) Using Too Much Debt?
Jul 28Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio
Jul 15Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?
Jun 29Shareholder Returns
QGEN | US Life Sciences | US Market | |
---|---|---|---|
7D | -3.7% | -2.5% | -0.7% |
1Y | 4.3% | 15.4% | 32.5% |
Return vs Industry: QGEN underperformed the US Life Sciences industry which returned 15.4% over the past year.
Return vs Market: QGEN underperformed the US Market which returned 32.5% over the past year.
Price Volatility
QGEN volatility | |
---|---|
QGEN Average Weekly Movement | 3.3% |
Life Sciences Industry Average Movement | 8.7% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: QGEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: QGEN's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 5,900 | Thierry Bernard | www.qiagen.com |
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Qiagen N.V. Fundamentals Summary
QGEN fundamental statistics | |
---|---|
Market cap | US$9.68b |
Earnings (TTM) | US$72.70m |
Revenue (TTM) | US$1.94b |
133.2x
P/E Ratio5.0x
P/S RatioIs QGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QGEN income statement (TTM) | |
---|---|
Revenue | US$1.94b |
Cost of Revenue | US$936.99m |
Gross Profit | US$1.00b |
Other Expenses | US$930.52m |
Earnings | US$72.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.33 |
Gross Margin | 51.71% |
Net Profit Margin | 3.75% |
Debt/Equity Ratio | 42.8% |
How did QGEN perform over the long term?
See historical performance and comparison